JW Pharmaceutical Corp (001065) — Capital Reinvestment Ratio
JW Pharmaceutical Corp (001065) has a Capital Reinvestment Ratio of 0.21x as of September 2025, meaning it reinvests 0% of its operating cash flow (₩46.92 Billion) in capital expenditures (₩9.80 Billion). See debt-free asset ratio of JW Pharmaceutical Corp to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
JW Pharmaceutical Corp Capital Reinvestment Ratio (2014–2024)
This chart tracks JW Pharmaceutical Corp's Capital Reinvestment Ratio across 10 annual periods. Check JW Pharmaceutical Corp total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for JW Pharmaceutical Corp (2014–2024)
Year-by-year Capital Reinvestment Ratio for JW Pharmaceutical Corp from 2014 to 2024. For live market cap and broader valuation context, see 001065 market cap overview.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.35x | ₩79.39 Billion | ₩28.14 Billion | ▼ -24.1% |
| 2023 | 0.47x | ₩87.16 Billion | ₩40.71 Billion | ▲ +167.3% |
| 2022 | 0.17x | ₩56.76 Billion | ₩9.92 Billion | ▼ -57.6% |
| 2021 | 0.41x | ₩18.12 Billion | ₩7.47 Billion | ▲ +109.7% |
| 2020 | 0.20x | ₩63.05 Billion | ₩12.39 Billion | ▲ +17.5% |
| 2019 | 0.17x | ₩55.53 Billion | ₩9.28 Billion | ▲ +0.9% |
| 2018 | 0.17x | ₩52.11 Billion | ₩8.64 Billion | ▼ -26.1% |
| 2017 | 0.22x | ₩33.45 Billion | ₩7.50 Billion | ▼ -84.9% |
| 2016 | 1.49x | ₩6.74 Billion | ₩10.02 Billion | ▲ +56.2% |
| 2014 | 0.95x | ₩7.28 Billion | ₩6.93 Billion | — |